ArticleBMJ open2023
Lung cancer mortality in the wake of the changing smoking epidemic: a descriptive study of the global burden in 2020 and 2040.
Article in BMJ open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation.Advances in therapy · 2025Trial
- A trans-omics gene-smoking interaction study of lung cancer based on consortium data.American journal of respiratory and critical care medicine · 2026Article
- Prognostic Significance and Immune Landscape of Neuroendocrine Differentiation-Related Genes in Non-Small Cell Lung Cancer.Biological procedures online · 2026Article
- Trends in socioeconomic inequalities in preventable lung cancer mortality in three major Spanish cities of the Valencian Community, 2000-2015.Scientific reports · 2026Article
- Oral paraneoplastic manifestations and findings associated with extra-oral surgically treated malignancies: a prospective cross-sectional study of 300 cases.World journal of surgical oncology · 2026Article
- RNA sequencing reveals differential expression of circular RNAs in human small cell lung cancer.Scientific reports · 2026Article
- Unveiling the multitarget anticancer potential of Cochlospermum religiosum: phytochemical profiling, molecular docking, and in vitro/in vivo validation.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Metabolic reprogramming and lung cancer focused on roles, mechanism, and clinical prospects of circRNAs: a narrative review.Frontiers in oncology · 2026Review
- Latency period of lung cancer in relation to tobacco smoking in Korea.Epidemiology and health · 2026Observational
- Next-generation immune cell therapies for lung cancer: advances in CAR-T, NK, and TIL strategies.Frontiers in medicine · 2026Review
- The tumor microenvironment in lung cancer: Heterogeneity, therapeutic resistance and emerging treatment strategies (Review).International journal of oncology · 2026Review
- [Treatment of metastatic non-small cell lung cancer].Innere Medizin (Heidelberg, Germany) · 2025Review
- A NAMs-Based Microphysiological System for Metastasis and Mechanobiology Studies.Thoracic research and practice · 2025Article
- Emerging Trends in Global Lung Cancer Burden.Seminars in respiratory and critical care medicine · 2025Review
- Deep learning in histopathology images for prediction of oncogenic driver molecular alterations in lung cancer: a systematic review and meta-analysis.Translational lung cancer research · 2025Article
- The Current Roadmap of Lung Cancer Biology, Genomics and Racial Disparity.International journal of molecular sciences · 2025Review
- Predicting the clinical prognosis of non-small cell lung cancer patients by predicting ALOX5 expression: a radiomics model.Journal of thoracic disease · 2025Article
- Predictive model for sarcopenia in patients with non-small cell lung cancer and malignant pleural effusion.BMC cancer · 2025Article
- Silencing of LINC01278 promotes sensitivity of non-small cell lung cancer cells to osimertinib by targeting miR-324-3p/ZFX axis.Cytotechnology · 2025Article
- A Holistic Approach to Implementing Artificial Intelligence in Lung Cancer.Indian journal of surgical oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesLung cancer (LC) is the leading cause of cancer death in 2020, responsible for almost one in five (18.0%) deaths. This paper provides an overview of the descriptive epidemiology of LC based on national mortality estimates for 2020 from the International Agency for Research on Cancer (IARC), and in the context of recent tobacco control policies. DESIGN AND
settingFor this descriptive study, age-standardised mortality rates per 100 000 person-years of LC for 185 countries by sex were obtained from the GLOBOCAN 2020 database and stratified by Human Development Index (HDI). LC deaths were projected to 2040 based on demographic changes alongside scenarios of annually increasing, stable or decreasing rates from the baseline year of 2020.
resultsLC mortality rates exhibited marked variations by geography and sex. Low HDI countries, many of them within sub-Saharan Africa, tend to have low levels of mortality and an upward trend in LC deaths is predicted for both sexes until 2040 according to demographic projections, irrespective of trends in rates. In very high HDI countries, including Europe, Northern America and Australia/New Zealand, there are broadly decreasing trends in men whereas in women, rates are still increasing or reaching a plateau.
conclusionThe current and future burden of LC in a country or region largely depends on the present trajectory of the smoking epidemic in its constituent populations, with distinct gender differences in smoking patterns, both in transitioning and transitioned countries. Further elevations in LC mortality are expected worldwide, raising important social and political questions, especially in low-income and middle-income countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.